Enfusion (ENFN)
(Delayed Data from NYSE)
$8.04 USD
+0.15 (1.90%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $8.03 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for Enfusion, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 175 | 150 | 112 | 80 | 59 |
Cost Of Goods | 58 | 47 | 32 | 21 | 17 |
Gross Profit | 117 | 103 | 80 | 58 | 42 |
Selling & Adminstrative & Depr. & Amort Expenses | 105 | 115 | 356 | 52 | 28 |
Income After Depreciation & Amortization | 12 | -12 | -276 | 6 | 14 |
Non-Operating Income | -2 | -1 | -1 | 0 | 0 |
Interest Expense | -2 | 0 | 5 | 2 | 1 |
Pretax Income | 11 | -12 | -282 | 4 | 13 |
Income Taxes | 2 | 1 | 1 | 0 | 0 |
Minority Interest | 3 | -6 | -124 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 9 | -13 | -282 | 4 | 13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 6 | -8 | -158 | 4 | 13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 22 | -6 | -272 | 8 | 15 |
Depreciation & Amortization (Cash Flow) | 10 | 6 | 4 | 2 | 1 |
Income After Depreciation & Amortization | 12 | -12 | -276 | 6 | 14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 129.43 | 85.39 | 83.17 | NA | NA |
Diluted EPS Before Non-Recurring Items | 0.09 | -0.10 | 0.55 | NA | NA |
Diluted Net EPS (GAAP) | 0.07 | -0.10 | -2.26 | NA | NA |
Fiscal Year end for Enfusion, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 49.46 | 48.05 | 46.49 | 44.36 | 42.72 |
Cost Of Goods | 15.96 | 16.17 | 15.62 | 14.51 | 14.21 |
Gross Profit | 33.49 | 31.88 | 30.86 | 29.85 | 28.51 |
SG&A, R&D, and Dept/Amort Expenses | 30.79 | 32.99 | 28.73 | 27.16 | 26.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | 2.70 | -1.11 | 2.13 | 2.69 | 2.45 |
Non-Operating Income | 0.25 | 0.24 | -1.60 | 0.34 | -1.26 |
Interest Expense | NA | 0.00 | -1.64 | 0.00 | 0.00 |
Pretax Income | 2.95 | -0.88 | 2.18 | 3.03 | 1.19 |
Income Taxes | 0.40 | -0.12 | 1.28 | 0.37 | 0.19 |
Minority Interest | 0.72 | -0.22 | 0.28 | 0.83 | 0.37 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 2.55 | -0.76 | 0.90 | 2.66 | 1.00 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 1.83 | -0.54 | 0.62 | 1.83 | 0.63 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 89.51 | 127.77 | 127.84 | 129.86 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -0.01 | 0.01 | 0.02 | 0.02 |
Diluted Net EPS (GAAP) | 0.02 | -0.01 | 0.01 | 0.02 | 0.01 |